Trevi Therapeutics, Inc.
TRVI
$6.47
$0.121.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.70% | 5.18% | 28.66% | 21.03% | 3.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.05% | 55.74% | 58.54% | 57.42% | 34.19% |
| Operating Income | -37.05% | -55.74% | -58.54% | -57.42% | -34.19% |
| Income Before Tax | -46.08% | -72.13% | -72.26% | -70.26% | -41.23% |
| Income Tax Expenses | -11.11% | -138.46% | 73.33% | -14.29% | 190.00% |
| Earnings from Continuing Operations | -45.95% | -72.02% | -72.88% | -70.32% | -42.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.95% | -72.02% | -72.88% | -70.32% | -42.07% |
| EBIT | -37.05% | -55.74% | -58.54% | -57.42% | -34.19% |
| EBITDA | -37.17% | -55.95% | -58.73% | -57.36% | -33.97% |
| EPS Basic | -37.02% | -68.65% | -68.78% | -68.72% | -40.61% |
| Normalized Basic EPS | -37.14% | -68.87% | -68.50% | -64.27% | -39.60% |
| EPS Diluted | -37.02% | -68.65% | -68.78% | -68.72% | -40.61% |
| Normalized Diluted EPS | -37.14% | -68.87% | -68.50% | -64.27% | -39.60% |
| Average Basic Shares Outstanding | 6.56% | 1.97% | 2.37% | 0.92% | 1.00% |
| Average Diluted Shares Outstanding | 6.56% | 1.97% | 2.37% | 0.92% | 1.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |